Universal-Beteiligungs- und Servicegesellschaft
CLDX icon

Universal-Beteiligungs- und Servicegesellschaft’s Celldex Therapeutics CLDX Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.29M Buy
195,788
+125,735
+179% +$4.06M 0.01% 777
2026
Q1 		$2.22M Buy
70,053
+37,790
+117% +$1.03M ﹤0.01% 1202
2025
Q4 		$876K Buy
32,263
+12,966
+67% +$342K ﹤0.01% 1534
2025
Q3 		$499K Buy
19,297
+2,802
+17% +$64.9K ﹤0.01% 1746
2025
Q2 		$336K Buy
16,495
+1,661
+11% +$32.3K ﹤0.01% 1798
2025
Q1 		$269K Buy
+14,834
New +$331K ﹤0.01% 1813

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's CLDX Position: Q2 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft increased its Celldex Therapeutics (CLDX) stake by 179% in Q2 2026, buying an estimated $4.06M and bringing the position to 195,788 shares worth $7.29M. The position accounts for 0.01% of the portfolio, ranked #777.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in CLDX in Q1 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Universal-Beteiligungs- und Servicegesellschaft held 195,788 shares of Celldex Therapeutics worth $7.29M as of Q2 2026.
  • Universal-Beteiligungs- und Servicegesellschaft bought 125,735 Celldex Therapeutics shares in Q2 2026, an estimated $4.06M.
  • Celldex Therapeutics made up 0.01% of Universal-Beteiligungs- und Servicegesellschaft's portfolio in Q2 2026, its #777 holding.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2026, filed 6 Aug 2026.